Home use of day-and-night hybrid closed-loop insulin delivery in suboptimally controlled adolescents with type 1 diabetes: A 3-week, free-living, randomized crossover trial

Diabetes Care

Volumn 39, Issue 11, 2016, Pages 2019-2025

  Tauschmann, Martin ^a   Allen, Janet M ^a   Wilinska, Malgorzata E ^a   Thabit, Hood ^a   Acerini, Carlo L ^a   Dunger, David B ^a   Hovorka, Roman ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN LISPRO; C PEPTIDE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADOLESCENT DISEASE; ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAILY LIFE ACTIVITY; DISEASE DURATION; DRUG DELIVERY DEVICE; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; FREE LIVING CONDITION; GLUCOSE SENSOR; HUMAN; HYBRID CLOSED LOOP INSULIN DELIVERY; INFORMED CONSENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; KETONURIA; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME; BLOOD; CHILD; DIABETES MELLITUS, TYPE 1; GLUCOSE BLOOD LEVEL; METABOLISM; QUESTIONNAIRE; TIME FACTOR; URINALYSIS;

ADOLESCENT; BLOOD GLUCOSE; C-PEPTIDE; CHILD; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; URINALYSIS;

EID: 84994238870     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1094     Document Type: Conference Paper

References (29)

1. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA; T1D Exchange Clinic Network. The T1D Exchange clinic registry. J Clin Endocrinol Metab 2012;97:4383-4389
2. Wood JR, Miller KM, Maahs DM, et al.; T1D Exchange Clinic Network. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care 2013;36:2035-2037
3. Miller KM, Foster NC, Beck RW, et al.; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971-978
4. Maftei O, Pena AS, Sullivan T, et al.; AdDIT Study Group. Early atherosclerosis relates to urinary albumin excretion and cardiovascular risk factors in adolescents with type 1 diabetes: Adolescent type 1 Diabetes cardio-renal Intervention Trial (AdDIT). Diabetes Care 2014;37: 3069-3075
5. Cho YH, Craig ME, Davis EA, et al.; Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial. Cardiac autonomic dysfunction is associated with high-risk albumin-to-creatinine ratio in young adolescents with type 1 diabetes in AdDIT (adolescent type 1 diabetes cardio-renal interventional trial). Diabetes Care 2015;38:676-681
6. Burdick J, Chase HP, Slover RH, et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics 2004;113:e221-e224
7. Vanderwel BW, Messer LH, Horton LA, et al. Missed insulin boluses for snacks in youth with type 1 diabetes. Diabetes Care 2010;33:507-508
8. Hofer SE, Heidtmann B, Raile K, et al.; DPVScience-Initiative and the German working group for insulin pump treatment in pediatric patients. Discontinuation of insulin pump treatment in children, adolescents, and young adults. A multicenter analysis based on the DPV database in Germany and Austria. Pediatr Diabetes 2010;11:116-121
9. Langendam M, Luijf YM, Hooft L, Devries JH, Mudde AH, Scholten RJ. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev 2012;1:CD008101
10. Bergenstal RM, Tamborlane WV, Ahmann A, et al.; STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311-320
11. Bergenstal RM, Klonoff DC, Garg SK, et al.; ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;369:224-232
12. Buckingham BA, Raghinaru D, Cameron F, et al.; In Home Closed Loop Study Group. Predictive low-glucose insulin suspension reduces duration of nocturnal hypoglycemia in children without increasing ketosis. Diabetes Care 2015; 38:1197-1204
13. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: A phase 2 randomised crossover trial. Lancet 2010;375:743-751
14. Elleri D, Allen JM, Kumareswaran K, et al. Closed-loop basal insulin delivery over 36 hours in adolescents with type 1 diabetes: randomized clinical trial. Diabetes Care 2013;36:838-844
15. Nimri R, Danne T, Kordonouri O, et al. The "Glucositter" overnight automated closed loop system for type 1 diabetes: A randomized crossover trial. Pediatr Diabetes 2013;14:159-167
16. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014;371:313-325
17. Haidar A, Legault L, Matteau-Pelletier L, et al. Outpatient overnight glucose control with dual-hormone artificial pancreas, singlehormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2015;3:595-604
18. Russell SJ, Hillard MA, Balliro C, et al. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: A randomised crossover trial. Lancet Diabetes Endocrinol 2016;4:233-243
19. Hovorka R, Elleri D, Thabit H, et al. Overnight closed-loop insulin delivery in young people with type 1 diabetes: A free-living, randomized clinical trial. Diabetes Care 2014;37: 1204-1211
20. Nimri R, Muller I, Atlas E, et al. Night glucose control with MD-Logic artificial pancreas in home setting: A single blind, randomized crossover trial-interim analysis. Pediatr Diabetes 2014;15:91-99
21. Thabit H, Tauschmann M, Allen JM, et al; APCam Consortium; AP@home Consortium. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 2015;373:2129-2140
22. Tauschmann M, Allen JM, Wilinska ME, et al. Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: A free-living, randomized clinical trial. Diabetes Care 2016;39:1168-1174
23. Elleri D, Allen JM, Biagioni M, et al. Evaluation of a portable ambulatory prototype for automated overnight closed-loop insulin delivery in young people with type 1 diabetes. Pediatr Diabetes 2012;13:449-453
24. Wilinska ME, Budiman ES, Taub MB, et al. Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies. J Diabetes Sci Technol 2009;3: 1109-1120
25. Wilinska ME, Chassin LJ, Acerini CL, Allen JM, Dunger DB, Hovorka R. Simulation environment to evaluate closed-loop insulin delivery systems in type 1 diabetes. J Diabetes Sci Technol 2010;4:132-144
26. Leelarathna L, Dellweg S, Mader JK, et al.; AP@home Consortium. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study. Diabetes Care 2014;37:1931-1937
27. Kropff J, Del Favero S, Place J, et al.; AP@home consortium. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: A randomised crossover trial. Lancet Diabetes Endocrinol 2015;3:939-947
28. Blauw H, van Bon AC, Koops R, DeVries JH; on behalf of the PCDIAB consortium. Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home. Diabetes Obes Metab 2016; 18:671-677
29. Barnard KD, Wysocki T, Allen JM, et al. Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents. BMJ Open Diabetes Res Care 2014;2:e000025